Germany Preclinical Cro Market Size & Outlook, 2023-2030

The preclinical cro market in Germany is expected to reach a projected revenue of US$ 579.9 million by 2030. A compound annual growth rate of 7.3% is expected of Germany preclinical cro market from 2024 to 2030.
Revenue, 2023 (US$M)
$354.6
Forecast, 2030 (US$M)
$579.9
CAGR, 2024 - 2030
7.3%
Report Coverage
Germany

Germany preclinical cro market highlights

  • The Germany preclinical cro market generated a revenue of USD 354.6 million in 2023 and is expected to reach USD 579.9 million by 2030.
  • The Germany market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
  • In terms of segment, toxicology testing was the largest revenue generating service in 2023.
  • Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.


Preclinical cro market data book summary

Market revenue in 2023USD 354.6 million
Market revenue in 2030USD 579.9 million
Growth rate7.3% (CAGR from 2023 to 2030)
Largest segmentToxicology testing
Fastest growing segmentBioanalysis and DMPK studies
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology
Key market players worldwideEurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA


Other key industry trends

  • In terms of revenue, Germany accounted for 6.2% of the global preclinical cro market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 748.8 million by 2030.

Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the Germany preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.


The country is one of the major locations for preclinical and clinical trials along with the UK in Europe. Advancements in technology and quality clinical resources are some of the primary factors expected to propel this market over the forecast period. In addition, government initiative for clinical research activities has accelerated the growth of preclinical CRO market.

Furthermore, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2021, the German pharmaceutical industry invested USD 9.26 billion (EUR 8.54 billion) in R&D. In addition, as per the German Trade and Investment (GTAI), the pharmaceutical sector had the highest research intensity among all industries at 14.4% of revenues reinvested in R&D in 2020.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Preclinical CRO Market Companies

Name Profile # Employees HQ Website

Germany preclinical cro market size, by service, 2018-2030 (US$M)

Germany Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)

Germany preclinical cro market size, by service, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more